Latest Conference Articles

Comparing Cost-Effectiveness of Antidiabetic Therapies with Cardiovascular Benefit

Comparing Cost-Effectiveness of Antidiabetic Therapies with Cardiovascular Benefit

November 19th 2020

AHA 2020

Gregory Weiss, MD, examines 4 studies presented at AHA Scientific Sessions 2020 comparing the cost-effectiveness of antidiabetic agents for reducing cardiovascular events.

AHA & AstraZeneca Push for Uptake of SGLT2 Inhibitors with TRANSLATE-HF Program

AHA & AstraZeneca Push for Uptake of SGLT2 Inhibitors with TRANSLATE-HF Program

November 18th 2020

AHA 2020

TRANSLATE-HF is a collaborative effort between the AHA and AstraZeneca with the goal of increasing and optimizing SGLT2 inhibitor use in US patients. Hear further insight lead author from the first of 6 TRANSLATE-HF studies, which was presented at AHA 2020.

Deepak Bhatt, MD: STRENGTH, REDUCE-IT, and DHA

Deepak Bhatt, MD: STRENGTH, REDUCE-IT, and DHA

November 17th 2020

AHA 2020

Deepak Bhatt, MD, MPH, offers his thoughts on the most important REDUCE-IT analyses released in 2020 and why he disagrees with the notion results of the STRENGTH trial somehow impact the use of icosapent ethyl in clinical settings.

Deepak Bhatt, MD: Sotagliflozin and Phase 3 Data from AHA 2020

Deepak Bhatt, MD: Sotagliflozin and Phase 3 Data from AHA 2020

November 17th 2020

AHA 2020

Deepak Bhatt, MD, MPH, offers his thoughts on the results of SCORED and SOLOIST as well as diving deeper into the implications of the data for sotagliflozin and SGLT2 inhibitors moving forward.

George Bakris, MD: Cardiovascular Benefits of Finerenone in FIDELIO-DKD

George Bakris, MD: Cardiovascular Benefits of Finerenone in FIDELIO-DKD

November 17th 2020

AHA 2020

George Bakris, MD, offers further insight into the cardiovascular outcomes analysis of FIDELIO-DKD presented at AHA 2020.

Sotagliflozin, a Dual SGLT2/1 Inhibitor, Shows Promise in Phase 3 Trials

Sotagliflozin, a Dual SGLT2/1 Inhibitor, Shows Promise in Phase 3 Trials

November 17th 2020

AHA 2020

Data from the phase 3 SOLOIST-WHF and SCORED trials suggest sotagliflozin was associated with significant reductions in death from CVD in patients with worsening heart failure and significant reductions in blood glucose levels among patients with moderate to severe kidney impairment.

Phase 2 Trial Suggests Evinacumab Cuts LDL-C by 50% in Refractory Hypercholesterolemia

Phase 2 Trial Suggests Evinacumab Cuts LDL-C by 50% in Refractory Hypercholesterolemia

November 16th 2020

AHA 2020

Data from a phase 2 trial suggests evinacumab, in both subcutaneous and intravenous doses, were effective at lowering LDL-C in patients with refractory hypercholesterolemia.

First-Line Ablation More Effective than Antiarrhythmic Drugs for Atrial Fibrillation

First-Line Ablation More Effective than Antiarrhythmic Drugs for Atrial Fibrillation

November 16th 2020

AHA 2020

Results of the EARLY-AF study suggest first-line ablation may be a better approach for patients with symptomatic atrial fibrillation than first-line antiarrhythmic drugs.

HARP-MINOCA Outlines Benefit of OCT, Cardiac CMR When Diagnosing Heart Attacks

HARP-MINOCA Outlines Benefit of OCT, Cardiac CMR When Diagnosing Heart Attacks

November 15th 2020

AHA 2020

Data from HARP-MINOCA suggests use of OCT and cardiac CMR could help determine cause of symptoms in women presenting with MINOCA.

Rivaroxaban Noninferior to Warfarin in AFib Patients w/ Bioprosthetic Mitral Valves

Rivaroxaban Noninferior to Warfarin in AFib Patients w/ Bioprosthetic Mitral Valves

November 15th 2020

AHA 2020

Results of the RIVER trial suggest rivaroxaban was noninferior to warfarin for the study's composite endpoint of all-cause mortality, major cardiovascular events, and major bleeding.